anmelden
Novartis Aktie
130,56
EUR
-0,70
EUR
-0,53
%
122,44
CHF
-1,30
CHF
-1,05
%
Novartis jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Marktkap. 238,19 Mrd. EUR
KGV 18,30 Div. Rendite 3,38%WKN 904278
ISIN CH0012005267
Symbol NVSEF
AI Analyse
Werbung
Novartis Aktie Analyse
| 21.05.15 | Novartis overweight | JP Morgan Chase & Co. | |
| 12.05.15 | Novartis buy | Citigroup Corp. | |
| 29.04.15 | Novartis buy | Citigroup Corp. | |
| 28.04.15 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 24.04.15 | Novartis Hold | Deutsche Bank AG | |
| 24.04.15 | Novartis Outperform | Credit Suisse Group | |
| 23.04.15 | Novartis buy | S&P Capital IQ | |
| 21.04.15 | Novartis Outperform | BNP PARIBAS | |
|
Werbung
|
|||
| 21.04.15 | Novartis Outperform | Bernstein Research | |
| 16.04.15 | Novartis Hold | Société Générale Group S.A. (SG) | |
| 14.04.15 | Novartis neutral | Independent Research GmbH | |
| 14.04.15 | Novartis overweight | JP Morgan Chase & Co. | |
| 14.04.15 | Novartis buy | UBS AG | |
| 13.04.15 | Novartis buy | Jefferies & Company Inc. | |
| 08.04.15 | Novartis buy | UBS AG | |
| 01.04.15 | Novartis Equal weight | Barclays Capital | |
| 04.03.15 | Novartis Outperform | BNP PARIBAS | |
| 03.03.15 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 02.03.15 | Novartis buy | UBS AG | |
| 20.02.15 | Novartis buy | Jefferies & Company Inc. | |
| 09.02.15 | Novartis buy | Citigroup Corp. | |
| 28.01.15 | Novartis neutral | Morgan Stanley | |
| 28.01.15 | Novartis overweight | JP Morgan Chase & Co. | |
| 28.01.15 | Novartis Hold | Deutsche Bank AG | |
| 28.01.15 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 27.01.15 | Novartis Halten | Independent Research GmbH | |
| 26.01.15 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 23.01.15 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 22.01.15 | Novartis Outperform | BNP PARIBAS | |
| 22.01.15 | Novartis buy | UBS AG | |
| 21.01.15 | Novartis neutral | Morgan Stanley | |
| 21.01.15 | Novartis overweight | JP Morgan Chase & Co. | |
| 20.01.15 | Novartis Equal-Weight | Morgan Stanley | |
| 20.01.15 | Novartis neutral | Independent Research GmbH | |
| 19.01.15 | Novartis buy | Kepler Cheuvreux | |
| 16.01.15 | Novartis buy | UBS AG | |
| 16.01.15 | Novartis buy | Jefferies & Company Inc. | |
| 16.01.15 | Novartis buy | S&P Capital IQ | |
| 16.01.15 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 15.01.15 | Novartis Hold | Deutsche Bank AG | |
| 05.01.15 | Novartis overweight | JP Morgan Chase & Co. | |
| 15.12.14 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 12.12.14 | Novartis buy | UBS AG | |
| 09.12.14 | Novartis Neutral | Merrill Lynch & Co., Inc. | |
| 09.12.14 | Novartis Neutral | Merrill Lynch & Co., Inc. | |
| 03.12.14 | Novartis Equal-Weight | Morgan Stanley | |
| 28.11.14 | Novartis overweight | JP Morgan Chase & Co. | |
| 25.11.14 | Novartis Outperform | BNP PARIBAS | |
| 13.11.14 | Novartis buy | UBS AG | |
| 10.11.14 | Novartis buy | Jefferies & Company Inc. | |
Werbung
Werbung
